#emicizumab
LightNews LightNews
radishdoodles.bsky.social
I have a big old medical appointment tomorrow that's been booked for me months in advanced. But seriously, January 2nd??? It's like a cold slap back to reality of life, ha.
I asked for info about this new treatment plan and I got the pharmaceutical booklet and that's it.
A generic information booklet about hemlibra (emicizumab).
January 2, 2026 at 6:26 AM
hemehub.bsky.social
The second question of the day!

See the answer and explanation on the next slide.

#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation #GeneTherapy #Emicizumab #InternalMedicine #ClinicalTrials #BloodDisorders @htrstoday.bsky.social @thjournal.bsky.social @ash.edu.hematology.org
November 27, 2025 at 3:41 AM
hemehub.bsky.social
Today's first question!

See the answer and explanation on the next slide.

#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation #GeneTherapy #Emicizumab #ClinicalTrials #BloodDisorders @htrstoday.bsky.social @thjournal.bsky.social @sfthemostase.bsky.social @ash.edu.hematology.org
November 27, 2025 at 3:40 AM
hemehub.bsky.social
Facts about Hemophilia A: Rebalancing and RNA-Based Therapies

#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation #GeneTherapy #Emicizumab #ClinicalTrials #BloodDisorders @htrstoday.bsky.social @thjournal.bsky.social @sfthemostase.bsky.social @ash.edu.hematology.org
November 27, 2025 at 3:39 AM
hemehub.bsky.social
The second question of the day focuses on understanding complications in patients receiving fitusiran prophylaxis.

See the answer and explanation on the next slide!

#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation #GeneTherapy #Emicizumab #InternalMedicine #ClinicalTrials
November 25, 2025 at 3:09 AM
hemehub.bsky.social
Today’s first question focuses on why a child on regular recombinant Factor VIII prophylaxis may still experience several bleeding episodes each year.

See the answer and explanation on the next slide!

#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation #GeneTherapy #Emicizumab
November 25, 2025 at 3:09 AM
hemehub.bsky.social
Facts about Hemophilia A: Non-Factor (Substitution) Therapies

#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation #GeneTherapy #Emicizumab #ClinicalTrials #BloodDisorders @htrstoday.bsky.social @thjournal.bsky.social @sfthemostase.bsky.social @ash.edu.hematology.org
November 25, 2025 at 3:08 AM
hemehub.bsky.social
Today’s question focuses on the type of viral vector most commonly used in gene therapy trials for Hemophilia A.

See the answer and explanation on the next slide!

#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation #GeneTherapy #Emicizumab #InternalMedicine #ClinicalTrials
November 21, 2025 at 10:28 PM
hemehub.bsky.social
Facts about Hemophilia A: Treatment — Factor Replacement Era

#Hemophilia #BleedingDisorders #Hematology #RareDiseases #GeneTherapy #Emicizumab #InternalMedicine #ClinicalTrials #BloodDisorders @thjournal.bsky.social @htrstoday.bsky.social @sfthemostase.bsky.social @ash.edu.hematology.org
November 21, 2025 at 10:28 PM
hemehub.bsky.social
Today’s question focuses on safe management of breakthrough bleeding in a patient receiving emicizumab prophylaxis.

See the answer and explanation on the next slide!

#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation #GeneTherapy #Emicizumab #InternalMedicine #ClinicalTrials
November 20, 2025 at 8:37 PM
hemehub.bsky.social
Facts about Hemophilia A:

Additional information on diagnosis and screening

#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation #GeneTherapy #Emicizumab #InternalMedicine #ClinicalTrials #BloodDisorders @htrstoday.bsky.social @sfthemostase.bsky.social @thjournal.bsky.social
November 20, 2025 at 8:36 PM
hemehub.bsky.social
Facts about Hemophilia A: Diagnosis and Screening

#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation #GeneTherapy #Emicizumab #InternalMedicine #ClinicalTrials #BloodDisorders @thjournal.bsky.social @htrstoday.bsky.social @sfthemostase.bsky.social @ash.edu.hematology.org
November 17, 2025 at 11:10 PM
hemehub.bsky.social
Facts about Hemophilia A: Clinical Manifestations

#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation #GeneTherapy #Emicizumab #InternalMedicine #ClinicalTrials #BloodDisorders @htrstoday.bsky.social @thjournal.bsky.social @sfthemostase.bsky.social @athnnews.bsky.social
November 13, 2025 at 8:05 PM
hemehub.bsky.social
Today’s question highlights the cytokine responsible for joint damage in Hemophilia A.

See the answer and explanation on the next slide!

#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation #GeneTherapy #Emicizumab #InternalMedicine #ClinicalTrials #BloodDisorders
November 12, 2025 at 2:08 AM
melaniedaniel.bsky.social
Wonderful presentation by @mickaelrosa.bsky.social in the Science Fast and Furious session at ECTH2025 in Prague : effect of emicizumab focusing on monocytes/macrophages using single cell and transcriptomic data. Work from team 2 led by Professor @sophiesusen.bsky.social, UMR1011.
October 24, 2025 at 3:54 PM
tomreiser.bsky.social
ICYMI earlier this week - now available as a recording:
@ISTH.org @rpth.bsky.social Research Recap:
Activated prothrombin complex concentrate in patients receiving emicizumab prophylaxis
w/ Robert Sidonio, Cedric Hermans, @profmakris.bsky.social
RPTH Research Recap: Activated PCC in patients receiving emicizumab prophylaxis
Join us for this exciting webinar on the recent RPTH article: "Activated prothrombin complex concentrate in patients receiving emicizumab prophylaxis: from evidence to clinical practice." Join Author…
www.youtube.com
October 24, 2025 at 2:15 PM
unc-bcbp.bsky.social
Excited to share Leiderman lab's pub “Mathematical analysis of emicizumab: affinity-driven complex formation and lipid-surface reactions” in JTH! Their latest research shows fresh insights for next-gen therapies. Read more: www.sciencedirect.com/science/arti...
Leiderman lab at UNC
October 15, 2025 at 12:30 PM
unc-bcbp.bsky.social
The Leiderman lab’s latest paper is out in the JTH! They explored how emicizumab, a bispecific antibody for hemophilia A, works at the molecular level. This work offers new insights for designing future therapies. Read more about their findings:
www.sciencedirect.com/science/arti...
Mathematical analysis of emicizumab: affinity-driven complex formation and lipid-surface reactions
Emicizumab is a bispecific antibody that binds activated factor (F)IXa with 1-arm and FX with the other. Binding bridges FIXa and FX, replacing the fu…
www.sciencedirect.com
October 14, 2025 at 1:26 PM
haemnet.bsky.social
New in The Journal of Haemophilia Practice: a real-world study in the UAE shows improved clinical outcomes with #emicizumab #prophylaxis in children and adults with severe #haemophilia A. https://doi.org/10.2478/jhp-2025-0013

#HemeSky #MedSky #BloodSky
October 14, 2025 at 6:33 AM
tomreiser.bsky.social
Don't miss this @ISTH.org @rpth.bsky.social Research Recap on:
"Activated prothrombin complex concentrate in patients receiving emicizumab prophylaxis: from evidence to clinical practice."
📅 October 21, 15:15 UTC
🎙️Robert Sidonio, Cedric Hermans & @profmakris.bsky.social
bit.ly/4hbAYKE
October 10, 2025 at 2:15 PM
eahad.bsky.social
In this new episode of Meet the Author Interview, Maj Friberg Birkedal, Chair of the EAHAD Nurses Committee, shares insights on how the Neria™ Guard infusion set may ease pain and distress for children receiving emicizumab. 🎧 Listen here: open.spotify.com/episode/6HOi...
Meet the Author Ep. 8: A single centre experience with clinical use of Neria™ Guard as mode of pain and distress management in the administration of emicizumab in children
open.spotify.com
September 26, 2025 at 3:02 PM
haemnet.bsky.social
New in The Journal of Haemophilia Practice: results from a #qualitative study exploring the experiences of people with severe #haemophilia A in the #HemiNorth cohort switching from factor VIII prophylaxis to #emicizumab. Open access, here: https://loom.ly/MvtKKe4

#HemeSky #MedSky #BloodSky
September 17, 2025 at 5:53 AM
techwordnews.bsky.social
Hemophilia Patient from Thrissur has been administered with the treatment of prophylaxis emicizumab

The health department began to manage the treatment of prophylaxis of emicizumab to prevent episodes of bleeding in a 32 -year -old Thrissur woman suffering from congenital haemophilia A. He is…
Hemophilia Patient from Thrissur has been administered with the treatment of prophylaxis emicizumab
The health department began to manage the treatment of prophylaxis of emicizumab to prevent episodes of bleeding in a 32 -year -old Thrissur woman suffering from congenital haemophilia A. He is treated at Thrissur Government Medical College, after a detailed assessment of her condition and after advice by the medical team. Hemophilia is a rare inherited bleeding disorder in which blood is not properly torn due to absence or low levels of clotting proteins known as factors.
techwordnews.com
September 16, 2025 at 5:27 AM
rpth.bsky.social
This #commentary from Cedric HERMANS MD PhD FRCP discusses the use of activated prothrombinase complex concentrate in patients on #emicizumab.

www.rpthjournal.org/article/S247...

The original article being discussed is here:

www.rpthjournal.org/article/S247...
Cautious use of activated prothrombin complex concentrate in patients receiving emicizumab: new evidence and clinical considerations
Emicizumab (EMI), a bispecific monoclonal antibody that mimics the function of activated factor (F)VIII and is not recognized by anti-FVIII antibodies, has established itself as the prophylactic…
www.rpthjournal.org
September 8, 2025 at 6:03 PM
haemnet.bsky.social
In @eahad.bsky.social's latest podcast,
@majfbirkedal.bsky.social discusses using a subcutaneous drug delivery device to reduce treatment-related #pain in children with #haemophiliaA on #emicizumab. Read her paper in The Journal of Haemophilia Practice sciendo.com/article/10.2...

#HemeSky #MedSky
September 4, 2025 at 10:41 AM